Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | NSCLC | Research

Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review

Authors: Minyu Cheng, Yanfei Shao, Li Li, Menglao Jiang, Zhouye Song

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

There are differences in the pharmacoeconomics of Immune checkpoint blocking (ICB) therapies for the treatment of lung squamous cell carcinoma (LSCC). However, no corresponding review studies have fully discussed the cost-effectiveness of ICBs in treating LSCC. The aim of this paper is to systematically review and evaluate all available pharmacoeconomic studies of ICBs for LSCC.

Method

The inclusion criteria were based on the population, intervention, comparator, outcomes, and study designs. An electronic search was conducted by June 2023, and the following databases were used: PubMed, EMBASE, Cochrane Library, and Web of Science. Search keywords included ‘Carcinoma’, Non-Small-Cell Lung’, ‘Immunotherapy’, and ‘Economics, Medical’. The primary outcome was the cost-effectiveness analysis of ICB therapy in LSCC patients. Drummond Checklist was used to assess quality problems and possible bias in the study design of included pharmacoeconomic studies.

Results

This review searched 15 articles on the economic evaluation of ICB treatment for LSCC. After a qualitative review of 15 studies, we concluded that nivolumab is more cost-effective as a monotherapy than chemotherapy alone. In the combination regimen, pembrolizumab combined with chemotherapy appears to be the most cost-effective option at present, but for Chinese payers with LSCC, locally developed treatments such as sintilimab or toripalimab in combination with chemotherapy are more cost-effective.

Discussion

The inclusion of economic evaluation has heterogeneity in research design and outcomes, which can only support qualitative synthesis. Therefore, The results of this paper need to be treated with caution. For the Chinese market, instead of imported drugs, the possible cost-effectiveness of locally developed ICB therapies should be the focus of future research.
Appendix
Available only for authorised users
Literature
1.
Brown S, Banfill K, Aznar MC, Whitehurst P, Faivre Finn C. The evolving role of radiotherapy in non-small cell lung cancer. Br J Radiol. 2019;92(1104):20190524.PubMedPubMedCentralCrossRef
2.
Russo AE, Priolo D, Antonelli G, Libra M, McCubrey JA, Ferraù F. Bevacizumab in the treatment of NSCLC: patient selection and perspectives. Lung Cancer (Auckl). 2017;8:259–69.PubMed
3.
Niu Z, Jin R, Zhang Y, Li H. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. Signal Transduct Target Ther. 2022;7(1):353.PubMedPubMedCentralCrossRef
4.
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–54.ADSPubMedCrossRef
5.
Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J. 2005;11(6):449–60.PubMedCrossRef
6.
Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J. 2005;11(6):461–73.PubMedCrossRef
7.
8.
Low JL, Walsh RJ, Ang Y, Chan G, Soo RA. The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer. Ther Adv Med Oncol. 2019;11:1758835919870360.PubMedPubMedCentralCrossRef
9.
Paik PK, Shen R, Berger MF, Ferry D, Soria JC, Mathewson A, et al. A phase ib open-label Multicenter Study of AZD4547 in patients with advanced squamous cell lung cancers. Clin Cancer Res. 2017;23(18):5366–73.PubMedPubMedCentralCrossRef
10.
Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1–3 kinase inhibitor, in patients with Advanced Solid tumors Harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. J Clin Oncol. 2017;35(2):157–65.PubMedCrossRef
11.
Aggarwal C, Redman MW, Lara PN Jr., Borghaei H, Hoffman P, Bradley JD, et al. SWOG S1400D (NCT02965378), a phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway-activated stage IV squamous cell lung Cancer (Lung-MAP substudy). J Thorac Oncol. 2019;14(10):1847–52.PubMedPubMedCentralCrossRef
12.
Langer CJ, Redman MW, Wade JL, IIIrd, Aggarwal C, Bradley JD, Crawford J, et al. SWOG S1400B (NCT02785913), a phase II study of GDC-0032 (Taselisib) for previously treated PI3K-Positive patients with stage IV squamous cell lung Cancer (Lung-MAP sub-study). J Thorac Oncol. 2019;14(10):1839–46.PubMedPubMedCentralCrossRef
13.
Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, et al. Lung Master Protocol (Lung-MAP)-A biomarker-driven protocol for accelerating development of therapies for squamous cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015;21(7):1514–24.PubMedPubMedCentralCrossRef
14.
Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, et al. SWOG S1400C (NCT02154490)-A phase II study of Palbociclib for previously treated cell cycle gene alteration-positive patients with stage IV squamous cell lung Cancer (Lung-MAP substudy). J Thorac Oncol. 2019;14(10):1853–9.PubMedPubMedCentralCrossRef
15.
Forde PM, Kelly RJ, Brahmer JR. New strategies in lung cancer: translating immunotherapy into clinical practice. Clin Cancer Res. 2014;20(5):1067–73.PubMedCrossRef
16.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive non-small-cell Lung Cancer. N Engl J Med. 2016;375(19):1823–33.PubMedCrossRef
17.
Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for First-Line treatment of PD-L1-Selected patients with NSCLC. N Engl J Med. 2020;383(14):1328–39.PubMedCrossRef
18.
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus Chemotherapy for squamous non-small-cell Lung Cancer. N Engl J Med. 2018;379(21):2040–51.PubMedCrossRef
19.
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced squamous-cell non-small-cell Lung Cancer. N Engl J Med. 2015;373(2):123–35.PubMedPubMedCentralCrossRef
20.
Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, et al. Phase III trial of Ipilimumab Combined with Paclitaxel and Carboplatin in Advanced squamous non-small-cell Lung Cancer. J Clin Oncol. 2017;35(30):3449–57.PubMedCrossRef
21.
Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol. 2022;23(2):220–33.PubMedCrossRef
22.
Shi Y, Wu L, Yu X, Xing P, Wang Y, Zhou J, et al. Sintilimab versus Docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). Cancer Commun (Lond). 2022;42(12):1314–30.PubMedCrossRef
23.
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3):305–14.PubMedCrossRef
24.
Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, et al. Tislelizumab Versus Docetaxel in patients with previously treated Advanced NSCLC (RATIONALE-303): a phase 3, Open-Label, Randomized Controlled Trial. J Thorac Oncol. 2023;18(1):93–105.PubMedCrossRef
25.
Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592–604.PubMedCrossRef
26.
Huang M, Lopes GL, Insinga RP, Burke T, Ejzykowicz F, Zhang Y, et al. Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA. Immunotherapy. 2019;11(17):1463–78.PubMedCrossRef
27.
Huang M, Lou Y, Pellissier J, Burke T, Liu FX, Xu R, et al. Cost effectiveness of Pembrolizumab vs. Standard-of-care chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in the United States. PharmacoEconomics. 2017;35(8):831–44.PubMedPubMedCentralCrossRef
28.
Ding H, Xin W, Tong Y, Sun J, Xu G, Ye Z, et al. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: a systematic review. PLoS ONE. 2020;15(9):e0238536.PubMedPubMedCentralCrossRef
29.
Yang SC, Kunst N, Gross CP, Wang JD, Su WC, Wang SY. Cost-effectiveness of Nivolumab Plus Ipilimumab with and without chemotherapy for Advanced Non-small Cell Lung Cancer. Front Oncol. 2021;11:760686.PubMedPubMedCentralCrossRef
30.
Hu H, She L, Liao M, Shi Y, Yao L, Ding D, et al. Cost-effectiveness analysis of Nivolumab plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-small Cell Lung Cancer. Front Oncol. 2020;10:1649.PubMedPubMedCentralCrossRef
31.
Li J, Zhang T, Xu Y, Lu P, Zhu J, Liang W, et al. Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC. Immunotherapy. 2020;12(14):1067–75.PubMedCrossRef
32.
Peng Y, Zeng X, Peng L, Liu Q, Yi L, Luo X, et al. Cost-effectiveness of Nivolumab plus Ipilimumab Combined with two cycles of Chemotherapy as First-Line treatment in Advanced Non-small Cell Lung Cancer. Adv Ther. 2021;38(7):3962–72.PubMedCrossRef
33.
Insinga RP, Vanness DJ, Feliciano JL, Vandormael K, Traore S, Burke T. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. J Med Econ. 2018;21(12):1191–205.PubMedCrossRef
34.
Insinga RP, Vanness DJ, Feliciano JL, Vandormael K, Traore S, Ejzykowicz F, et al. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US. Curr Med Res Opin. 2019;35(7):1241–56.PubMedCrossRef
35.
Zeng X, Wan X, Peng L, Peng Y, Ma F, Liu Q, et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA. BMJ Open. 2019;9(12):e031019.PubMedPubMedCentralCrossRef
36.
Criss SD, Mooradian MJ, Watson TR, Gainor JF, Reynolds KL, Kong CY. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line treatment of metastatic nonsquamous non-small cell Lung Cancer in the United States. JAMA Netw Open. 2019;2(9):e1911952.PubMedPubMedCentralCrossRef
37.
Lin S, Luo S, Zhong L, Lai S, Zeng D, Rao X, et al. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer. Int J Clin Pharm. 2020;42(4):1175–83.PubMedCrossRef
38.
Li LY, Wang H, Chen X, Li WQ, Cui JW. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China. Chin Med J (Engl). 2019;132(23):2790–4.PubMedCrossRef
39.
Yu A, Huang E, Abe M, An K, Park SK, Park C. Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):381–93.PubMedCrossRef
40.
Liu S, Jiang N, Dou L, Li S. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China. Front Immunol. 2023;14:1172242.PubMedPubMedCentralCrossRef
41.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.PubMedPubMedCentralCrossRef
42.
Edwards DJCaPRT. A Guide To Health Economics for those Working in Public Health a concise desktop handbook. Public Health Wales. 2016.
43.
Chaudhary MA, Holmberg C, Lakhdari K, Smare C, Theriou C, Dale P, et al. Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data. J Med Econ. 2021;24(1):607–19.PubMedCrossRef
44.
Chen P, Wang X, Zhu S, Li H, Rui M, Wang Y, et al. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC. Front Public Health. 2022;10:956792.PubMedPubMedCentralCrossRef
45.
Cheng R, Zhou Z, Liu Q. Cost-effectiveness of first-line versus second-line use of domestic anti-PD-1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non-small cell lung cancer. Cancer Med. 2023;12(6):7389–97.PubMedCrossRef
46.
Chouaid C, Bensimon L, Clay E, Millier A, Levy-Bachelot L, Huang M, et al. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (> 50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung Cancer. 2019;127:44–52.PubMedCrossRef
47.
Gao L, Li SC. Modelled Economic evaluation of Nivolumab for the treatment of Second-Line Advanced or metastatic squamous non-small-cell Lung Cancer in Australia using both partition survival and Markov Models. Appl Health Econ Health Policy. 2019;17(3):371–80.PubMedCrossRef
48.
Goeree R, Villeneuve J, Goeree J, Penrod JR, Orsini L, Tahami Monfared AA. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes. J Med Econ. 2016;19(6):630–44.PubMedCrossRef
49.
Hu S, Tang Z, Harrison JP, Hertel N, Penrod JR, May JR, et al. Economic evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and non-squamous non-small cell Lung Cancer after prior chemotherapy in China. Pharmacoecon Open. 2023;7(2):273–84.PubMedPubMedCentralCrossRef
50.
Liu Q, Zhou Z, Luo X, Yi L, Peng L, Wan X, et al. Cost-effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in metastatic non-squamous and squamous NSCLC patients with PD-L1 expression ≥ 50. Front Pharmacol. 2021;12:803626.PubMedCrossRef
51.
Rothwell B, Kiff C, Ling C, Brodtkorb TH. Cost effectiveness of Nivolumab in patients with Advanced, previously treated squamous and non-squamous non-small-cell Lung Cancer in England. Pharmacoecon Open. 2021;5(2):251–60.PubMedCrossRef
52.
Li W, Wan L. Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China. Front Public Health. 2022;10:1015702.PubMedPubMedCentralCrossRef
53.
Shao T, Ren Y, Zhao M, Tang W. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China. Front Public Health. 2022;10:912921.PubMedPubMedCentralCrossRef
54.
Zhang M, Xu K, Lin Y, Zhou C, Bao Y, Zhang L, et al. Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China. Front Immunol. 2023;14:1169752.PubMedPubMedCentralCrossRef
55.
Zhao M, Shao T, Chi Z, Tang W. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: a sequential model. Front Public Health. 2023;11:1051484.PubMedPubMedCentralCrossRef
56.
Zhou K, Shu P, Zheng H, Li Q. Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective. Front Pharmacol. 2023;14:1133085.PubMedPubMedCentralCrossRef
57.
Liu Q, Luo X, Yi L, Zeng X, Tan C. First-line chemo-immunotherapy for extensive-stage small-cell lung Cancer: a United States-based cost-effectiveness analysis. Front Oncol. 2021;11:699781.PubMedPubMedCentralCrossRef
58.
Liu Q, Luo X, Peng L, Yi L, Wan X, Zeng X, et al. Nivolumab Versus Docetaxel for previously treated Advanced Non-small Cell Lung Cancer in China: a cost-effectiveness analysis. Clin Drug Investig. 2020;40(2):129–37.PubMedCrossRef
59.
Wang Z, Wu L, Li B, Cheng Y, Li X, Wang X, et al. Toripalimab Plus Chemotherapy for patients with treatment-naive Advanced Non-small-cell Lung Cancer: a Multicenter Randomized Phase III Trial (CHOICE-01). J Clin Oncol. 2023;41(3):651–63.PubMedCrossRef
60.
Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, et al. Sintilimab Plus Platinum and Gemcitabine as First-Line treatment for Advanced or metastatic squamous NSCLC: results from a Randomized, Double-Blind, phase 3 trial (ORIENT-12). J Thorac Oncol. 2021;16(9):1501–11.PubMedCrossRef
61.
Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, et al. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial. J Thorac Oncol. 2022;17(4):544–57.PubMedCrossRef
Metadata
Title
Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review
Authors
Minyu Cheng
Yanfei Shao
Li Li
Menglao Jiang
Zhouye Song
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12043-w

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

25-hydroxycholesterol promotes proliferation and metastasis of lung adenocarcinoma cells by regulating ERβ/TNFRSF17 axis

Research

Health-related risk behaviors among U.S. childhood cancer survivors: a nationwide estimate

Research

Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer

Study Protocol

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

Research

Upregulation of CENPM promotes breast carcinogenesis by altering immune infiltration

Research

Estimating smoking-attributable lung cancer mortality in Chinese adults from 2000 to 2020: a comparison of three methods
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits